Lenvatinib

From WikiMD.org
Jump to navigation Jump to search

Lenvatinib

Lenvatinib (pronounced len-VA-ti-nib) is a type of medication used primarily in the treatment of certain types of cancer. It is a multi-kinase inhibitor that works by blocking the action of certain proteins that signal cancer cells to grow and divide.

Etymology

The name "Lenvatinib" is derived from the pharmaceutical company Eisai Co.'s internal code for the drug, "E7080", and the "-nib" suffix common to kinase inhibitors.

Usage

Lenvatinib is used to treat differentiated thyroid cancer that is no longer responsive to radioactive iodine treatment. It is also used in combination with everolimus for the treatment of advanced renal cell carcinoma after one prior anti-angiogenic therapy, and for the treatment of hepatocellular carcinoma in patients who have not received prior systemic therapy.

Side Effects

Common side effects of Lenvatinib include hypertension, diarrhea, decreased appetite, weight loss, and nausea. Serious side effects can include liver problems, high blood pressure, heart problems, a type of lung problem known as pneumonitis, and kidney problems.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski